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Abstract 
Background: Neuropathologically, Alzheimer’s disease (AD) is characterised by 
accumulation of a 42 amino acid peptide called amyloid β (Aβ42) in extracellular senile 
plaques together with intraneuronal inclusions of hyperphosphorylated tau protein in 
neurofibrillary tangles and neuronal degeneration. These changes are reflected in the 
cerebrospinal fluid (CSF), the volumes and production rates of which vary considerably 
between individuals, by reduced concentration of Aβ42, increased concentration of 
phosphorylated tau (P-tau) protein and increased concentration of total tau (T-tau) protein, 
respectively.  
 
Findings: We addressed the outstanding question if CSF concentrations of Aβ42, P-tau and T-
tau, as well as a number of other AD-related CSF biomarkers, are influenced by variations in 
subcortical, ventricular and spinal CSF volumes, as assessed by magnetic resonance imaging 
(MRI) volumetry, in 19 cognitively normal healthy volunteers (mean age 70.6, SD 3.6 years). 
We also assessed the potential association of these biomarkers with production rates of CSF. 
Negative correlations were seen between the concentrations of three CSF biomarkers 
(albumin ratio, Aβ38, and Aβ40), and ventricular CSF volume, but apart from this finding, no 
significant correlations were observed.  
 
Conclusions: These results speak against inter-individual variations in CSF volume and 
production rate as important confounds in the AD biomarker research field.  
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Background 
Cerebrospinal fluid (CSF) biomarkers are increasingly used in research on and the clinical 
evaluation of patients with Alzheimer’s disease (AD), a common neurodegenerative disorder 
characterized by accumulation of senile plaques and neurofibrillary tangles in the brain and 
progressive neuroaxonal degeneration [1]. Senile plaques are mainly composed of a 42 amino 
acid aggregation-prone peptide called amyloid β (Aβ42). This peptide can be measured in the 
CSF; low levels reflect Aβ pathology in the brain, which sequesters newly produced Aβ42 
with lower levels being able to diffuse into the CSF. Neurofibrillary tangles are intraneuronal 
aggregates composed of hyperphosphorylated forms of the intra-axonal protein tau (P-tau). 
Neurons with such inclusions eventually die and release P-tau into the CSF. AD patients thus 
typically have increased CSF P-tau levels, which is the most AD-specific CSF biomarker 
finding. Neuroaxonal degeneration and loss in AD is reflected in a general manner in the CSF 
by increased levels of total tau (T-tau), i.e., tau determined by assays that measure all forms of 
tau, irrespective of phosphorylation state. A typical pattern of CSF biomarker changes in AD 
is thus decreased levels of Aβ42 and increased levels of P-tau and T-tau [2].  
 
A42 is produced from Aβ precursor protein (APP), a transmembraneous protein with one 
transmembrane domain, a large extracellular domain and a smaller intracellular domain, by 
sequential cleavages of two enzymes, called β- and γ-secretase [3]. β-Secretase-mediated APP 
cleavage results in the release of a soluble fragment of APP called sAPPβ. The remaining stub 
of APP then undergoes γ-secretase cleavage which splits the molecule into (i) Aβ fragments 
of varying length, the most well-studied being Aβ38, Aβ40 and Aβ42, that are secreted, and 
(ii) the APP intracellular domain (AICD), which may function as an intracellular secondary 
messenger and transcription factor. Aβ42 is self-adhesive and may initiate self-perpetuating 
Aβ aggregation in a prion-like manner [4]. Aβ38 and Aβ40 are less aggregation-prone and 
easier to clear from the brain parenchyma into the CSF. If APP is not cleaved by β-secretase, 
it may enter another processing pathway in which α-secretase cleaves the protein in the 
middle of the Aβ domain, which results in the release of a soluble fragment called sAPPα. All 
these molecules can be measured in CSF and are, with the exception of A42, typically 
unchanged in AD [2].  
 
CSF T-tau, P-tau and Aβ42 may now be used to support a diagnosis of mild cognitive 
impairment or dementia due to AD according to revised diagnostic research criteria [5-8]. 
This has made it essential to learn more about potential confounding factors when these 
biomarkers are assessed. Several pre-analytical and analytical factors, e.g., type of CSF 
collection tube, aliquot volume and assay format, have been identified, which has resulted in 
the establishment of standard operating procedures for the whole procedure, from sampling to 
analysis [9]. However, two potential confounders have to our knowledge not been examined 
in detail before: CSF volumes and production rate, for which there are known and quite 
substantial inter-individual variations [10-12]  
Methods 
 
Subjects 
Volunteers born 1930 to 1942 were randomly recruited through the population registry of the 
City of Gothenburg and the Swedish retired people’s organisation between 2005 and 2007. 
Volunteers with neurological disorders, psychiatric illness, nephropathy, back problems, 
spinal operation, drug or alcohol abuse, contrast agent hypersensitivity or claustrophobia were 
excluded from the study during the recruitment process or the following investigation by two 
experienced neurologists. No individual was on treatment with any psychopharmacological 
drugs or centrally working analgesics. Basic blood tests measuring full blood count, sodium, 
potassium, blood sugar, calcium, sedimentation rate, kidney- and liver function were 
performed and found normal. Twenty-two healthy individuals were originally included in the 
study but 3 were excluded due to blood contamination of the CSF sample at the lumbar 
puncture, resulting in a final study group of 19 subjects (9 men and 10 women) with a mean 
age (SD) of 70.4 (3.7) years (Table 1).  
 
Ethics 
The Regional Ethics and Radiation Protection Committee in Gothenburg approved the study 
and informed consent was obtained from all participants.  
 
ICP, CSF production rate and CSF sampling  
CSF was collected by lumbar puncture (LP) in the L3/L4 interspace. All lumbar punctures 
were performed at approximately 11 am with the individuals placed in the left lateral 
recumbent position. A small pillow was placed under the head and the individuals were told 
to remain as still as possible. No torsion of the neck was allowed nor was speech if not urgent. 
The LP needle was 0.70 x 75 mm (22 gauge x 3 in.). The resting ICP was recorded for 10 
minutes before CSF sampling followed by calculation of the CSF production rate as described 
[10, 13, 14]  
Ten to twelve milliliters of CSF were collected in polypropylene tubes to minimize 
adsorbance of proteins to the test tube wall, aliquoted and stored at -80°C pending analysis. 
Prior to freezing, a small CSF aliquot was subjected to cell counting. More than 500 
erythrocytes per μL of CSF were considered a significant blood contamination that might 
influence the biomarker results and led to exclusion from the study (3 out of 22 originally 
included subjects were excluded in this manner). Serum was collected by venepuncture at the 
same time as the spinal tap. 
 
Imaging 
Magnetic resonance imaging (MRI) was performed with a Philips Gyroscan Intera 1.5T MR 
system (R11.1, R1.5.4 and R2.1) using the manufacturer’s synergi-spine 5 element surface 
coil (Philips, Eindhoven, The Netherlands). Manual segmentation of the intracranial, 
ventricles  and brain  volumes were performed on the magnetic resonance diffusion-weighted 
images data using QBrain software (Version 2.0; Medis Medical Imaging Systems BV, 
Leiden, the Netherlands). Whole-brain diffusion-weighted images  were collected using a spin 
echo pulse sequence with the following parameters: 25 slices, slice thickness 4 mm, interslice 
gap 1.5 mm, repetition time 3760 ms, echo time 90 ms, 3 averages, field of view 230×230 
mm, acquisition matrix 160×112, reconstructed matrix 256×256. 
Ventricular volumes  included the volume of the lateral, third and fourth ventricles. 
Intracranial and brain volumes  were the volume of the intracranial cavity and brain tissue 
(white and grey matter) from the foramen of magnum to the vertex. The intracranial 
subarachnoid CSF volume  was computed by subtracting brain and ventricular volumes from 
the intracranial volume. Local thresholding was used to segment and define the edges of each 
intracranial volume as described in previous studies [15]. QBrain computed automatically the 
volumes as the sum of the segmented areas multiplied by the sum of slice thickness and 
intersection gap. Spinal volumes were retrieved from the images as previously described and 
have been reported before [16]. The operator was blinded from the CSF biomarkers findings. 
 
Biochemical measurements 
Albumin levels in serum and CSF were measured by immunonephelometry on a Beckman 
Immage Immunochemistry system (Beckman Instruments, Beckman Coulter, Brea, CA, 
USA). The albumin ratio was calculated as CSF albumin (mg/L)/serum albumin (g/L) and 
was used as a measure of the blood-brain barrier function. T-tau was measured using a 
sandwich ELISA (INNOTEST hTAU-Ag, Fujirebio, Ghent, Belgium) specifically constructed 
to measure all tau isoforms irrespective of phosphorylation status. Tau phosphorylated at 
threonine 181 (P-tau) was measured using a sandwich ELISA (INNOTEST Phospho-
Tau[181P], Fujirebio). Aβ-related biomarkers (A38, A40, A42, secreted amyloid 
precursor protein  [sAPP] and secreted amyloid precursor protein  [sAPP]) were 
analyzed using Meso Scale assays (Meso Scale Discovery, Rockville, MD, USA) according to 
kit inserts. All samples were analyzed on the same plates using the same batch of reagents by 
board-certified laboratory technicians who were blinded to clinical information. Intra-assay 
coefficients of variation were below 10% for all analytes. 
 
Statistics 
Correlations were measured using Spearman’s rho (rs) while Mann-Whitney U test was 
employed for group comparisons. Prism 6 (GraphPad Software, La Jolla, CA, USA) was used 
for all statistical analysis and a p-value of less than 0.05 was considered significant.  
 
 
Results 
 
Demographics and gender differences 
There were no differences in ICP, CSF volumes, CSF production rate or CSF biomarker 
levels between men and women, except for intracranial subarachnoid volumes which were 
lower in the female group (mean 244, SD 58 mL) compared to the males (mean 298, SD 36 
mL; p=0.026). Only the intracranial subarachnoid volumes  were  associated with age 
(rs=0.59, p=0.01).  
 
Tau markers 
CSF concentrations of T-tau and P-tau did not correlate with ICP, CSF volumes or CSF 
production rate (Figure 1A and B).  
 
Blood-brain barrier function 
CSF albumin concentration volume did not correlate with ICP, CSF volumes or CSF 
production rate, while CSF/serum albumin ratio, the best established biomarker for blood-
brain barrier function, correlated with the spinal CSF volume, (Figure 1C and D and Figure 
2A). 
 
Aβ-related markers 
CSF concentrations of Aβ38, Aβ40, Aβ42, sAPPα or sAPPβ did not correlate with ICP, CSF 
production rate or spinal or intracranial subarachnoid CSF volumes. However, negative 
correlations were seen between the ventricular CSF volume and both Aβ38, and Aβ40 (Figure 
1E-I and Figure 2B-C).  
 
 
 
Discussion  
This is to our knowledge the first study addressing the potential association of AD-related 
CSF biomarkers and CSF-related biophysical variables in healthy volunteers. We detected a 
negative correlation of CSF Aβ38, and Aβ40 with ventricular CSF volume, but not with 
subarachnoid or spinal CSF volumes which constitute the largest part of the total CSF 
volume. Since the ventricular, subarachnoid and spinal CSF volumes communicate freely 
with each other, the negative correlations cannot be explained by mere dilution of Aβ. 
Furthermore, such a dilution effect should have been seen for tau markers as well. Instead, the 
results suggest that ventricular volume may correlate with brain changes that influence Aβ 
metabolism in a manner that leads to lower concentrations of the proteins in lumbar CSF. For 
example, periventricular hypo-metabolism in normal pressure hydrocephalus has been shown 
to correlate with lower levels of CSF Aβ38, Aβ40 and Aβ42; changes that are reversed by 
successful shunt therapy [17]. One earlier study using Alzheimer’s Disease Neuro-imaging 
Initiative (ADNI) data also obtained a negative correlation of ventricular CSF volume with 
CSF Aβ42 concentration, leading the authors to hypothesize that the correlation might be 
explained by more Aβ pathology in patients with larger ventricles and that altered CSF-blood-
brain barrier functions may underlie the association [18]. However, this study did not take 
into account the other CSF volumes or the concentrations of the non-amyloidogenic Aβ38 and 
Aβ40 peptides. Cerebral β-amyloidosis results in a selective reduction in CSF Aβ42 
concentration but does not change Aβ38 or Aβ40 concentrations (Rosén et al., Neuromol Med 
(2012) 14:65–73). When all three markers are altered in the same direction, a more general 
effect on Aβ metabolism has to be suspected. Furthermore, we detected a negative correlation 
of the best-established biomarker for blood-CSF barrier dysfunction, the albumin ratio [19], 
with the spinal CSF volume.  
 
CSF T-tau or P-tau concentrations were not influenced by any of the CSF volumes measured, 
which speaks against the approach to relate CSF T-tau and P-tau concentrations to ventricular 
volume as a means to increase the clinical usefulness of these markers [20].  
 
There were no correlations between CSF production rate or ICP and any of the examined CSF 
biomarkers speaking against these variables as potential confounds in AD biomarker studies.  
 
We conclude that the evidence in the present study rules out a number of potential confounds 
in CSF biomarker studies of AD-related processed. CSF volumes and production rate show no 
significant correlation with most of the examined markers and the negative correlation of 
ventricular CSF volume with CSF Aβ38, and Aβ40 in addition to the negative correlation 
between the albumin ratio and the spinal CSF volume most likely represent something else 
than mere dilution and should thus probably not be corrected for.   
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Hade vi inte med en tabell 1 tidigare med all demografi + volymer och biomarkördata? Tror 
att det vore bra att ha en sådan.  
 
Figure legends 
 
Figure 1. Spearman’s rank correlation coefficients (rs) between different CSF related 
biophysical variables and CSF concentrations of (A) T-tau, (B) P-tau, (C) Albumin ratio, (D) 
Albumin, (E) sAPP, (F) sAPP, (G) A38, (H) A, and (I) A. Significant correlations 
are highlighted in grey and the error bars represent the 95% confidence interval. 
Abbreviations: ICP, intracranial pressure; IC-SA, intracranial subarachnoidal. 
 
Figure 2. Scatter plots of (A) albumin ratio versus spinal CSF volume, (B) A, and (C) 
A versus ventricular CSF volume. 
